John Mongan, DO
Hematology & Oncology · Malta, NYNPI 1134235765
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations.
Across 112 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$283
- AbbVie$193
- Takeda Pharmaceuticals U.S.A., Inc.$165
- Johnson & Johnson$128
- Pfizer$107
- Incyte Corporation$100
- plus $2K from 33 others
Across 2 payments — averaging $30,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$60K
What the payments were for
- Food & beverage$2,39197%
- Education$863%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 11 | $283 |
| AbbVie | 7 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $165 |
| Johnson & Johnson(2 entities) | 6 | $128 |
| Pfizer | 6 | $107 |
| Incyte Corporation | 4 | $100 |
| Astellas Pharma US Inc | 5 | $97 |
| EMD Serono, Inc. | 4 | $97 |
| Novartis | 5 | $95 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $88 |
| Exelixis Inc. | 4 | $84 |
| Epizyme, Inc. | 4 | $78 |
| Array Biopharma Inc | 3 | $73 |
| Pharmacosmos Therapeutics Inc. | 3 | $67 |
| GSK | 3 | $62 |
| Amgen | 3 | $61 |
| Merck | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 3 | $52 |
| Eisai Inc. | 2 | $47 |
| Beigene USA, Inc. | 3 | $46 |
| Genentech USA, Inc. | 3 | $46 |
| Lilly USA, LLC | 2 | $45 |
| Sanofi | 2 | $45 |
| Blueprint Medicines Corporation | 2 | $40 |
| Puma Biotechnology, Inc. | 2 | $40 |
| Dova Pharmaceuticals | 2 | $32 |
| Gilead(2 entities) | 2 | $28 |
| Acrotech Biopharma Inc. | 1 | $24 |
| AstraZeneca | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| Immunogen, Inc. | 1 | $20 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Bayer | 1 | $19 |
| Bristol Myers Squibb | 1 | $18 |
| Tempus AI, Inc | 1 | $16 |
| Sobi, Inc | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Clovis Oncology, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,477 in reported general payments places this provider in the 55th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 39 | $570,888 |
| PomalystPomalidomide | 22 | $495,515 |
| CalquenceAcalabrutinib Maleate | 41 | $469,555 |
| ImbruvicaIbrutinib | 22 | $360,931 |
| XtandiEnzalutamide | 27 | $333,033 |
| KisqaliRibociclib Succinate | 14 | $237,039 |
| InqoviDecitabine/Cedazuridine | 21 | $167,104 |
| Abiraterone Acetate | 65 | $129,079 |
| XareltoRivaroxaban | 59 | $69,500 |
| EliquisApixaban | 55 | $62,885 |
| Exemestane | 41 | $8,136 |
| Demeclocycline Hcl | 11 | $5,789 |
| Anastrozole | 175 | $3,753 |
| Hydroxyurea | 67 | $1,697 |
| Fentanyl | 22 | $1,659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $283 | $495,51522 claims |
| AstraZenecaCalquence | $22 | $469,55541 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $88 | $360,93122 claims |
| Astellas Pharma US IncXtandi | $97 | $333,03327 claims |
| NovartisKisqali | $95 | $237,03914 claims |
| Johnson & JohnsonXarelto | $128 | $69,50059 claims |
| PfizerEliquis | $107 | $62,88555 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Malta
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.